Blood biologic markers of stroke: Improved management, reduced cost?

被引：11

作者：

Baird A.E. ^{[1
]}

机构：

[1] Stroke Neuroscience Unit, NINDS/NIH, Bethesda, MD 20892-1294

来源：

Current Atherosclerosis Reports | 2006年 / 8卷 / 4期

关键词：

Ischemic Stroke; Stroke Risk; Chronic Granulomatous Disease; Stroke Recurrence; Systolic Blood Pressure Level;

D O I：

10.1007/s11883-006-0003-2

中图分类号：

学科分类号：

摘要：

Identifying blood biomarkers may be of particular value in neurologic disorders such as stroke because of the difficulty in directly studying the brain and its blood vessels. Markers of brain injury, inflammation, excitotoxicity, and oxidative damage have been evaluated for their value in stroke diagnosis, treatment, and management, but none have proved to be sensitive or specific enough for routine clinical use. However, new cellular and molecular profiling approaches using the peripheral blood offer the potential for identifying panels of genes and proteins by increasing specificity while maintaining sensitivity. Furthermore, the first biomarker for predicting stroke risk associated with atherosclerosis (lipoprotein-associated phospholipase A2) was recently approved by the United States Food and Drug Administration. The ultimate aim for stroke biomarkers is to develop rapid, easy to use, widely available, and inexpensive diagnostic tests that can be used in the clinic and in clinical trials. Copyright © 2006 by Current Science Inc.

引用

页码：267 / 275

页数：8

共 50 条

[1]

Hill M.D., Diagnostic biomarkers for stroke: A stroke neurologist's perspective, Clin Chem, 51, pp. 2001-2002, (2005)

[2]

Goldstein L.B., Simel D.L., Is this patient having a stroke?, JAMA, 293, pp. 2391-2402, (2005)

[3]

Norris J.W., Hachinski V.C., Misdiagnosis of stroke, Lancet, 1, pp. 328-331, (1982)

[4]

Hand P.J., Kwan J., Lindley R.I., Et al., Distinguishing between stroke and mimic at the bedside. The Brain Attack Study, Stroke, 37, pp. 769-775, (2006)

[5]

Kidwell C.S., Chalela J.A., Saver J.L., Et al., Comparison of MRI and CT for detection of acute intracerebral hemorrhage, JAMA, 292, pp. 1823-1830, (2004)

[6]

Baird A.E., Dambrosia J., Janket S., Et al., A three-item scale for the early prediction of stroke recovery, Lancet, 357, pp. 2095-2099, (2001)

[7]

Mayer S.A., Brun N.C., Begtrup K., Et al., Recombinant activated factor VII for acute intracerebral hemorrhage, N Engl J Med, 352, pp. 777-785, (2005)

[8]

Lees K.R., Zivin J.A., Ashwood T., Et al., NXY-059 for acute ischemic stroke, N Engl J Med, 354, pp. 588-600, (2006)

[9]

Hsieh K.M., Blumenthal H.T., Serum lactic dehydrogenase levels in various disease states, Proc Soc Exp Biol Med, 91, pp. 626-630, (1956)

[10]

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework, Clin Pharmacol Ther, 69, pp. 89-95, (2001)

← 1 2 3 4 5 →